Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

A strike is when more than 25 per cent of shareholders are against a company proposal, in this case executive pay, paving the way for a second ballot on whether to spill the board. Shareholders have ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

CSL (ASX:CSL) has attracted fresh attention after its Broadmeadows plasma fractionation facility in Australia was named the Overall Winner of the 2025 Facility of the Year Award by the International ...

A rare 2023 BMW M4 CSL with only 1,600 miles is up for sale on Bring a Trailer. This lightweight, high-performance coupe looks almost new and demands attention. The Ultimate Driving Machine never ...

CSL has partnered with Dutch biotech VarmX to co-develop VMX-C001, a potential first-in-class treatment to restore blood coagulation in patients on FXa inhibitors. The agreement includes an upfront ...

Nearly 15 per cent of CSL’s global workforce will be reduced in the biggest shake-up of the company in decades aimed at “simplifying the business”. CSL employs about 30,000 staff globally. Its share ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...